LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers hope ...
Please provide your email address to receive an email when new articles are posted on . Luxturna maintained long-term improvements in ambulatory vision, light sensitivity and visual field in patients ...
LUXTURNA is administered by subretinal injection to each eye on separate days within a close interval, but no fewer than 6 days apart. Please see the Indication and Important Safety Information ...
FDA approved Spark Therapeutics’ gene therapy Luxturna™ (voretigene neparvovec-rzyl) for treating children and adults with the rare inherited blindness disorder biallelic RPE65 mutation-associated ...
LUXTURNA would be first gene therapy for a genetic disease approved in both U.S. and EU LUXTURNA would be first and only gene therapy approved in EU to treat patients with vision loss due to inherited ...
Luxturna is the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene. Luxturna (voretigene neparvovec-rzyl; Spark Therapeutics) ...
LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers hope ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results